Clinical Trial Update: A Phase II Neoadjuvant Study of Enzalutamide, Abiraterone Acetate, Dutasteride and Degarelix in Men With Localized Prostate Cancer Pre-prostatectomy [Phase 2]

View source ↗

Summary

A Phase II neoadjuvant study of enzalutamide, abiraterone acetate, dutasteride, and degarelix in men with localized prostate cancer was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Localized Prostate Cancer
• Prostate Cancer

Drugs mentioned

• Abiraterone acetate (Zytiga) (abiraterone acetate)
• Degarelix (Firmagon) (degarelix)
• Dutasteride (Avodart) (dutasteride)
• Enzalutamide (Xtandi) (enzalutamide)

Snippet

Sponsor: Kenneth Pienta, MD | Conditions: Prostate Cancer, Localized Prostate Cancer | Phase 2 | Status: WITHDRAWN